32.12
price up icon1.10%   0.35
after-market Handel nachbörslich: 31.59 -0.53 -1.65%
loading
Schlusskurs vom Vortag:
$31.77
Offen:
$32
24-Stunden-Volumen:
2.36M
Relative Volume:
1.64
Marktkapitalisierung:
$20.61B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
21.41
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+11.37%
1M Leistung:
+24.06%
6M Leistung:
+70.67%
1J Leistung:
+35.58%
1-Tages-Spanne:
Value
$31.74
$32.24
1-Wochen-Bereich:
Value
$28.36
$32.24
52-Wochen-Spanne:
Value
$17.23
$32.24

Genmab Adr Stock (GMAB) Company Profile

Name
Firmenname
Genmab Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
2,639
Name
Twitter
@Genmab
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
GMAB's Discussions on Twitter

Vergleichen Sie GMAB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GMAB
Genmab Adr
32.12 19.56B 2.62B 966.70M 1.09B 1.5004
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.85 103.64B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
600.00 63.59B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.99 60.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
791.59 46.96B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
345.17 36.81B 4.56B -176.77M 225.30M -1.7177

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-23 Hochstufung Guggenheim Neutral → Buy
2025-04-01 Herabstufung Bernstein Mkt Perform → Underperform
2025-03-11 Hochstufung William Blair Mkt Perform → Outperform
2025-02-13 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-08 Eingeleitet Redburn Atlantic Buy
2024-09-04 Fortgesetzt Morgan Stanley Equal-Weight
2024-08-20 Herabstufung JP Morgan Overweight → Neutral
2024-07-15 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-02-23 Hochstufung BMO Capital Markets Market Perform → Outperform
2024-01-22 Herabstufung Citigroup Neutral → Sell
2023-12-06 Hochstufung UBS Neutral → Buy
2023-11-10 Hochstufung Deutsche Bank Hold → Buy
2023-11-08 Hochstufung DNB Markets Sell → Buy
2023-10-18 Eingeleitet Exane BNP Paribas Underperform
2023-09-06 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-08-24 Eingeleitet BTIG Research Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-31 Eingeleitet UBS Neutral
2023-05-12 Eingeleitet Morgan Stanley Underweight
2022-12-20 Herabstufung Citigroup Buy → Neutral
2022-11-14 Eingeleitet William Blair Mkt Perform
2022-11-11 Herabstufung Deutsche Bank Buy → Hold
2022-06-24 Eingeleitet BMO Capital Markets Market Perform
2022-05-02 Eingeleitet Cowen Market Perform
2022-03-16 Hochstufung UBS Neutral → Buy
2022-01-31 Hochstufung H.C. Wainwright Neutral → Buy
2022-01-03 Herabstufung Guggenheim Buy → Neutral
2021-12-01 Eingeleitet Berenberg Sell
2021-09-16 Herabstufung Jefferies Buy → Hold
2021-09-07 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-08-24 Herabstufung H.C. Wainwright Buy → Neutral
2021-04-20 Eingeleitet Deutsche Bank Buy
2021-01-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-09-23 Herabstufung Bryan Garnier Neutral → Sell
2020-09-08 Eingeleitet SVB Leerink Mkt Perform
2020-06-25 Herabstufung Credit Suisse Outperform → Neutral
2020-04-23 Eingeleitet Credit Suisse Outperform
2020-02-24 Bestätigt H.C. Wainwright Buy
2020-01-13 Eingeleitet SunTrust Buy
2019-12-12 Herabstufung Deutsche Bank Buy → Hold
2019-09-13 Hochstufung BofA/Merrill Neutral → Buy
2019-09-12 Hochstufung JP Morgan Neutral → Overweight
2019-08-12 Eingeleitet Guggenheim Buy
2019-08-12 Eingeleitet Morgan Stanley Overweight
2019-08-12 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Genmab Adr Aktie (GMAB) Neueste Nachrichten

pulisher
Oct 01, 2025

Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World

Oct 01, 2025
pulisher
Sep 30, 2025

TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Sep 30, 2025
pulisher
Sep 30, 2025

Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Sep 30, 2025
pulisher
Sep 29, 2025

Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga

Sep 29, 2025
pulisher
Sep 29, 2025

European Stocks Higher to Kick Off the Week - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp - Defense World

Sep 29, 2025
pulisher
Sep 29, 2025

Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Placera.se

Sep 29, 2025
pulisher
Sep 25, 2025

Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World

Sep 25, 2025
pulisher
Sep 25, 2025

Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World

Sep 25, 2025
pulisher
Sep 24, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High Following Analyst Upgrade - Defense World

Sep 24, 2025
pulisher
Sep 23, 2025

Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst Upgrade - MarketBeat

Sep 23, 2025
pulisher
Sep 16, 2025

Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 16, 2025
pulisher
Sep 15, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Sep 15, 2025
pulisher
Sep 15, 2025

Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 15, 2025
pulisher
Sep 14, 2025

Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighStill a Buy? - MarketBeat

Sep 14, 2025
pulisher
Sep 10, 2025

Northern Trust Corp Raises Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 10, 2025
pulisher
Sep 09, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P. - MarketBeat

Sep 09, 2025
pulisher
Sep 08, 2025

Graham Capital Management L.P. Acquires 16,035 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 08, 2025
pulisher
Sep 05, 2025

Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 05, 2025
pulisher
Sep 04, 2025

Orbis Allan Gray Ltd Has $111.82 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 04, 2025
pulisher
Sep 03, 2025

Synovus Financial Corp Takes $633,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 03, 2025
pulisher
Sep 02, 2025

Tema Etfs LLC Boosts Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 02, 2025
pulisher
Sep 01, 2025

Cresset Asset Management LLC Has $244,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Sep 01, 2025
pulisher
Aug 27, 2025

Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World

Aug 27, 2025
pulisher
Aug 27, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Aug 27, 2025
pulisher
Aug 22, 2025

Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World

Aug 22, 2025
pulisher
Aug 21, 2025

IBD Rating Upgrades: MINISO Group Holding ADR Flashes Improved Technical Strength - inkl

Aug 21, 2025
pulisher
Aug 20, 2025

IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - Investor's Business Daily

Aug 20, 2025
pulisher
Aug 19, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 19, 2025
pulisher
Aug 19, 2025

IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl

Aug 19, 2025
pulisher
Aug 18, 2025

What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World

Aug 18, 2025
pulisher
Aug 18, 2025

IBD Rating Upgrades: HCA Healthcare Shows Improved Technical Strength - inkl

Aug 18, 2025
pulisher
Aug 15, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World

Aug 15, 2025
pulisher
Aug 11, 2025

What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World

Aug 11, 2025
pulisher
Aug 09, 2025

Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks

Aug 08, 2025

Finanzdaten der Genmab Adr-Aktie (GMAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$86.28
price down icon 0.48%
$104.51
price up icon 2.25%
$36.49
price up icon 0.47%
$152.80
price up icon 3.75%
biotechnology ONC
$345.17
price up icon 2.99%
Kapitalisierung:     |  Volumen (24h):